We are live on
!
Find out more
ACP
Acuta Capital Partners Portfolio holdings
AUM
$142M
1-Year Est. Return
783.79%
This Fund
S&P 500
This Quarter
Est. Return
+15.97%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$119M
AUM Growth
-$29.2M
(-20%)
Cap. Flow
-$43.3M
Cap. Flow
% of AUM
-36.49%
Top 10 Holdings %
Top 10 Hldgs %
54.42%
Holding
88
New
24
Increased
10
Reduced
14
Closed
37
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Iovance Biotherapeutics
IOVA
|
+$7.54M |
| 2 |
CEMP
Cempra, Inc.
CEMP
|
+$5.12M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$4.16M |
| 4 |
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
|
+$3.02M |
| 5 |
FOLD
Amicus Therapeutics
FOLD
|
+$2.93M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
|
+$2.97M |
| 2 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
+$2.9M |
| 3 |
VOLC
VOLCANO CORPORATION COM STK
VOLC
|
+$2.74M |
| 4 |
PTX
Pernix Therapeutics Holdings, Inc.
PTX
|
+$2.42M |
| 5 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
+$2.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.05% |
| 2 | Consumer Discretionary | 2.48% |
| 3 | Industrials | 0.85% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
| $21.4M | 18% |
1,964,565
+331,845
| +20% | +$2.93M |
|
|
2
Iovance Biotherapeutics
IOVA
$1.93B
| $8.1M | 6.83% |
+669,196
| New | +$7.54M |
|
|
CEMP
3
DELISTED
Cempra, Inc.
CEMP
| $5.85M | 4.92% |
+170,400
| New | +$5.12M |
|
|
ALIM
4
DELISTED
Alimera Sciences
ALIM
| $5.29M | 4.45% |
70,321
-133
| -0.2% | -$10.5K |
|
|
BEAT
5
DELISTED
BioTelemetry, Inc.
BEAT
| $4.26M | 3.59% |
481,069
-2,803
| -0.6% | -$28.3K |
|
|
6
Ascendis Pharma A/S
ASND
$16B
| $3.97M | 3.34% |
+228,612
| New | +$4.16M |
|
7
Larimar Therapeutics
LRMR
$413M
| $3.96M | 3.34% |
8,333
-22
| -0.3% | -$10.4K |
|
8
LeMaitre Vascular
LMAT
$2.37B
| $3.91M | 3.29% |
466,279
+3,279
| +0.7% | +$25.7K |
|
|
PTX
9
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
| $3.74M | 3.15% |
35,000
-25,408
| -42% | -$2.42M |
|
|
OXFD
10
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $3.13M | 2.64% |
+222,226
| New | +$3.02M |
|
11
Insmed
INSM
$21.3B
| $3.12M | 2.63% |
150,000
+136,846
| +1,040% | +$2.41M |
|
|
RRM
12
DELISTED
RR MEDIA LTD ORD SHS (ISR)
RRM
| $3.11M | 2.62% |
405,424
+4,000
| +1% | +$29.1K |
|
13
Build-A-Bear
BBW
$424M
| $2.95M | 2.48% |
150,000
+61,260
| +69% | +$1.25M |
|
|
CASM
14
DELISTED
CAS Medical Systems, Inc.
CASM
| $2.88M | 2.43% |
2,160,000
+1,637,533
| +313% | +$2.36M |
|
15
IRIDEX
IRIX
$14.4M
| $2.52M | 2.12% |
235,517
+26,584
| +13% | +$258K |
|
16
PUT
iShares Russell 2000 ETF
IWM
$81.5B
| $2.49M | 2.09% |
20,000
-210,000
| -91% | -$25.3M |
|
|
CORV
17
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
| $2.2M | 1.85% |
237,600
-65,877
| -22% | -$631K |
|
18
Orthofix Medical
OFIX
$496M
| $2.15M | 1.81% |
60,000
-7,058
| -11% | -$222K |
|
19
Insulet
PODD
$11.8B
| $2.08M | 1.75% |
+62,265
| New | +$2.1M |
|
20
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$806B
| $2.06M | 1.74% |
+10,000
| New | +$2.06M |
|
21
Aurinia Pharmaceuticals
AUPH
$1.87B
| $1.88M | 1.58% |
+430,000
| New | +$1.7M |
|
|
DCOY
22
Decoy Therapeutics
DCOY
$2.31M
| – | – |
0
| – | – |
|
|
CBMX
23
DELISTED
CombiMatrix Corporation
CBMX
| $1.67M | 1.41% |
58,683
+1,798
| +3% | +$49.9K |
|
|
AVID
24
DELISTED
Avid Technology Inc
AVID
| $1.5M | 1.27% |
+100,818
| New | +$1.45M |
|
|
NDRM
25
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $1.39M | 1.17% |
+103,167
| New | +$1.27M |
|
Similar funds
EC
YEPX
SR
IA
MAM
HA
VVM
KCAM
Acuta Capital Partners's Q1 2015 Portfolio in Review
As of Q1 2015, Acuta Capital Partners held 88 positions worth $119M, down 20% from $148M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Acuta Capital Partners withdrew a net $43.3M in Q1 2015, closing 37 positions and reducing 14 holdings. Its most notable exit was Tetraphase Pharmaceuticals, Inc., an estimated $2.97M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 48% a quarter earlier, followed by Consumer Discretionary and Industrials.
Against the trend, Acuta Capital Partners opened a new position in Iovance Biotherapeutics worth $8.1M.
- Acuta Capital Partners's largest Q1 2015 buy was Iovance Biotherapeutics: 669,196 shares worth $8.1M.
- Acuta Capital Partners added most to Amicus Therapeutics in Q1 2015, an estimated $2.93M increase.
- Acuta Capital Partners's biggest Q1 2015 reduction was Pernix Therapeutics Holdings, Inc., cutting an estimated $2.42M.
- Acuta Capital Partners fully exited Tetraphase Pharmaceuticals, Inc. in Q1 2015, selling an estimated $2.97M.
- Acuta Capital Partners's ten largest holdings make up 54% of its $119M portfolio in Q1 2015.
- Acuta Capital Partners opened 24 new positions and closed 37 in Q1 2015.
- Acuta Capital Partners's portfolio value fell 20% quarter-over-quarter to $119M.
Based on Acuta Capital Partners's 13F filing for Q1 2015, filed 15 May 2015.